Attention AACR Annual Meeting 2017 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 14 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 11 12 13 14 presentations: 1 to 25 of 326
Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
David M Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Howard Burris
Sarah Cannon Research Institute, Nashville, TN, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
Ryan J Sullivan
Harvard Medical School/MGH, Boston, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Alex A. Adjei
Mayo Clinic, Rochester, MN, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study
Birgit Geoerger
Inst. Gustave Roussy, Villejuif, France
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Yael P Mosse
Children's Hospital of Philadelphia, Philadelphia, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Silvia Marsoni
Grande Ospedale Metropolitano Niguarda, Milano, Italy
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Rodrigo Dienstmann
Vall dĀ“Hebron Inst. of Oncology, Barcelona, Spain
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Somatic HLA mutations and neoantigen identification for immunotherapy analyses
Sachet A Shukla
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Dynamics of genomic and neoantigen landscape during immune checkpoint blockade
Valsamo Anagnostou
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Integrative clinical and genomic analysis of solid tumors treated with immune checkpoint blockade
Jeffrey E Hammerbacher
Icahn School Of Medicine At Mount Sinai, New York, NY, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Infiltrating immune cell signatures and genomic determinants of immune recognition in diverse tumors
Ash A. Alizadeh
Stanford Univ., Stanford, CA, United States
from AACR Annual Meeting 2017 on April 1, 2017 10:15 AM-12:15 PM
Panel Discussion
Laleh Amiri-Kordestani
FDA, Silver Spring, MD, United States
Javid M. Moslehi
Vanderbilt Univ. School of Medicine, Nashville, TN, United States
George D. Demetri
Dana-Farber Cancer Inst. and Harvard Med, Boston, MA, United States
David Feltquate
Bristol-Myers Squibb, New York, NY, United States
Shiv Pillai
Harvard Medical School, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
Suzanne L. Topalian
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 1, 2017 1:00 PM-2:45 PM
Invited Speaker
David Feltquate
Bristol-Myers Squibb, New York, NY, United States
from AACR Annual Meeting 2017 on April 1, 2017 1:00 PM-2:45 PM
Invited Speaker
Shiv Pillai
Harvard Medical School, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 1:00 PM-2:45 PM
Invited Speaker
Suzanne L. Topalian
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 1, 2017 1:00 PM-2:45 PM
Introduction
Cornelia Liu Trimble
Johns Hopkins Univ., Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
High-dimensional immune monitoring of tumor tissues for cancer immunotherapy
Sacha Gnjatic
Icahn School of Medicine at Mount Sinai, New York, NY, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
Targeting pathogen-induced malignancies: Lessons learned from adoptive T cell transfer for merkel cell carcinoma
Aude G. Chapuis
Fred Hutchinson Cancer Research Ctr., Seattle, WA, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
Developing a biomarker platform to serve targeted therapy and immunotherapy
Keith T Flaherty
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
High-dimensional analyses of the mucosal microenvironment in precancerous, intraepithelial cervical HPV disease
Cornelia L. Trimble
Johns Hopkins Univ., Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
Invited Speaker
Daniel S. Chen
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2017 on April 2, 2017 7:00 AM-8:00 AM
Invited Speaker
Sara A. Courtneidge
Oregon Health & Science Univ., Portland, OR, United States
from AACR Annual Meeting 2017 on April 2, 2017 7:00 AM-8:00 AM
Chair
Robert J. Gillies
Moffitt Cancer Center & Research Institute, Tampa, FL, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
<< first | < prev page: of 14 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 11 12 13 14 presentations: 1 to 25 of 326